AZTherapies

AZTherapies Overview

Founded 2011
Founded
Status Private
Employees 12
Employees
Latest Deal Type Series C
Latest Deal Amount $30.9M
Latest Deal Amount
Investors 6

AZTherapies General Information

Description

Developer of pharmaceutical drugs designed to provide treatment for multiple neurodegeneration and neuroinflammation-related CNS diseases. The company's products include ALZT-OP1 is a novel multi-action combination drug regimen which is use to modify disease progression by slowing down or halting Alzheimer's disease early in its development, enabling healthcare providers to cure Alzheimer's patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 200 Clarendon Street
  • 17th Floor
  • Boston, MA 02116
  • United States

AZTherapies Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AZTherapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 31-Jan-2020 $30.9M 000.00 Completed Generating Revenue
4. Later Stage VC (Series B) 16-Oct-2018 000.00 000.00 00000 Completed Generating Revenue
3. Later Stage VC 0000 000.00 Completed Generating Revenue
2. Later Stage VC (Series A) 06-Feb-2017 $16.4M $26.4M 00000 Completed Generating Revenue
1. Early Stage VC 06-Jan-2015 $10M $10M Completed Generating Revenue

AZTherapies Cap Table

To view AZTherapies‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A-2 0,000,000 00.000000 00.0 00.0 00 00.0 0.000
Series A-1 2,084,052 $0.000100 $3.33 $3.33 1x $3.33 4.58%
Series A 4,212,559 $0.000100 $4 $4 1x $4 9.26%

AZTherapies Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
ALSP Venture Capital-Backed San Diego, CA 00 00.000 0000000000 0
000000000 00000000 Venture Capital-Backed Cambridge, MA 00 000.00 0000000000 0 000.00
00000000 000000000 Venture Capital-Backed Boston, MA 00 000.00 000000000000 000.00
000 000000 Venture Capital-Backed Cambridge, MA 0 000.00 0000000000 0 000.00
000000 00000000000 Venture Capital-Backed Cambridge, MA 0 000.00 00000000000 000.00

AZTherapies Executive Team (9)

Name Title Board Seat Contact Info
David Elmaleh Ph.D Founder, Chairman & Chief Executive Officer
Karen Reeves MD President & Chief Medical Officer
Brian Bartlett Chief Accounting Officer & Interim Chief Financial Officer
Jay Mohr Chief Operating & Business Officer and Head of Commercial Development
Keith Greenfield Board Member & Executive Vice President, Business Development

1 Former Executive

AZTherapies Board Members (8)

To view AZTherapies‘s full board member team, request access »
Name Representing Role Since
David Elmaleh Ph.D AZTherapies Founder, Chairman & Chief Executive Officer 000 0000
David Taft Self Board Member 000 0000
George Behrakis AZTherapies Board Member 000 0000
Gillian Sandler Self Board Member 000 0000
John Porter AZTherapies Board Member 000 0000

AZTherapies Investors (6)

To view AZTherapies‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cosine (NYC biotech investors) Other Minority 000 0000 000000 0
DRADS Holdings Venture Capital Minority 000 0000 000000 0
IBS Capital Hedge Fund Minority 000 0000 000000 0
Spinnaker Capital Group Hedge Fund Minority 000 0000 000000 0
Wexford Capital Asset Manager Minority 000 0000 000000 0

AZTherapies Acquisitions (1)

To view AZTherapies‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 24-Oct-2019 000000000000000000 Biotechnology 00000 0000000 00.0

Ready to get started?

Request a free trial